The cellular mechanisms by which adenosine evokes release of nitric oxide from rat aortic endothelium.
Adenosine and nitric oxide (NO) are important local mediators of vasodilatation. The aim of this study was to elucidate the mechanisms underlying adenosine receptor-mediated NO release from the endothelium. In studies on freshly excised rat aorta, second-messenger systems were pharmacologically modulated by appropriate antagonists while a NO-sensitive electrode was used to measure adenosine-evoked NO release from the endothelium. We showed that A1-mediated NO release requires extracellular Ca2+, phospholipase A2 (PLA2) and ATP-sensitive K+ (KATP) channel activation whereas A2A-mediated NO release requires extracellular Ca2+ and Ca2+-activated K+ (KCa) channels. Since our previous study showed that A1- and A2A-receptor-mediated NO release requires activation of adenylate cyclase (AC), we propose the following novel pathways. The K+ efflux resulting from A1-receptor-coupled KATP-channel activation facilitates Ca2+ influx which may cause some stimulation of endothelial NO synthase (eNOS). However, the increase in [Ca2+]i also stimulates PLA2 to liberate arachidonic acid and stimulate cyclooxygenase to generate prostacyclin (PGI2). PGI2 acts on its endothelial receptors to increase cAMP, so activating protein kinase A (PKA) to phosphorylate and activate eNOS resulting in NO release. By contrast, the K+ efflux resulting from A2A-coupled KCa channels facilitates Ca2+ influx, thereby activating eNOS and NO release. This process may be facilitated by phosphorylation of eNOS by PKA via the action of A2A-receptor-mediated stimulation of AC increasing cAMP. These pathways may be important in mediating vasodilatation during exercise and systemic hypoxia when adenosine acting in an endothelium- and NO-dependent manner has been shown to be important.
Ray
Clare J
CJ
Department of Physiology, The Medical School, University of Birmingham, Birmingham B15 2TT, UK. c.j.ray@bham.ac.uk
Marshall
Janice M
JM
D000241:Adenosine / Q000494:pharmacology*; D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects / Q000378:metabolism; D001030:Apamin / Q000494:pharmacology; D001095:Arachidonic Acids / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000378:metabolism; D066298:In Vitro Techniques; D051036:Large-Conductance Calcium-Activated Potassium Channels / Q000187:drug effects; D008297:Male; D009569:Nitric Oxide / Q000378:metabolism; D010455:Peptides / Q000494:pharmacology; D010741:Phospholipases A / Q000187:drug effects; D054467:Phospholipases A2; D051381:Rats; D017208:Rats, Wistar; D043682:Receptor, Adenosine A1 / Q000187:drug effects; D043683:Receptors, Adenosine A2 / Q000187:drug effects; D015290:Second Messenger Systems / Q000187:drug effects; D051640:Small-Conductance Calcium-Activated Potassium Channels / Q000187:drug effects; D014227:Triazines / Q000494:pharmacology; D014230:Triazoles / Q000494:pharmacology; D014665:Vasodilator Agents / Q000494:pharmacology*; D014970:Xanthines / Q000494:pharmacology
D001095:Arachidonic Acids; D051036:Large-Conductance Calcium-Activated Potassium Channels; D010455:Peptides; D043682:Receptor, Adenosine A1; D043683:Receptors, Adenosine A2; D051640:Small-Conductance Calcium-Activated Potassium Channels; D014227:Triazines; D014230:Triazoles; D014665:Vasodilator Agents; D014970:Xanthines; C097270:ZM 241385; C081565:arachidonyltrifluoromethane; D001030:Apamin; D009569:Nitric Oxide; C064719:iberiotoxin; C051360:1,3-dipropyl-8-cyclopentylxanthine; D010741:Phospholipases A; D054467:Phospholipases A2; D000241:Adenosine; D002118:Calcium